CD276 and neoplasm: CIML-NK or NK cell activated by using different strategies [151,173] could be also engineered with chimeric antigen receptors (CARs) specific for GD2 [174] or alternative tumor-associated molecules including B7-H3 whose targeting have already shown excellent preclinical data [25,175,176].